Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

Volume 20, Issue 1, December 2024 .

Source: Human Vaccines and Immunotherapeutics - February 26, 2024 Category: Allergy & Immunology Authors: Frank van den OuwelandNicola Charpentier Özlem TüreciRuben RizziFederico J. MensaClaudia LindemannShanti Pathera Medical Safety and Pharmacovigilance, BioNTech, Mainz, Germanyb Risk Management, BioNTech, Mainz, Germanyc BioNTech, Mainz, Germanyd Global Source Type: research